IncyteCARES

IncyteCARES May Be Able to Help You Access Jakafi

Get an overview of how IncyteCARES assists patients and healthcare providers in obtaining access to Jakafi and connects them to continuing support and resources. View the video to learn more.

IncyteCARES (Connecting to Access, Reimbursement, Education and Support) is a program designed to offer ongoing support and resources during your treatment with Jakafi. Whether you have an insurance question or just need to speak to a trained nurse regarding Jakafi, IncyteCARES is here to help.

Specifically, IncyteCARES offers:

  • Prescription insurance verification and prior authorization support
  • Free drug and co-pay assistance, for those who qualify
  • Referral to independent nonprofit organizations or foundations that may be able to provide financial assistance
  • Access to oncology nurses

IncyteCARES (Connecting to Access, Reimbursement, Education and Support)

The objective of IncyteCARES is to help patients gain access to Jakafi. Based on patients diagnosed with myelofibrosis who enrolled in the program between August 2012 and October 2014:

90%
of patients referred to the co-pay assistance program were eligible for assistance
96%
of prior authorizations were approved for Jakafi

Enroll in IncyteCARES

Learn how to enroll in the IncyteCARES program.

Indications and Usage

Jakafi is a prescription medicine used to treat people with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is also used to treat certain types of myelofibrosis.

Important Safety Information

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Skin cancers: Some people who take Jakafi have developed certain types of non-melanoma skin cancers. Tell your healthcare provider if you develop any new or changing skin lesions.

Increases in cholesterol: You may have changes in your blood cholesterol levels. Your healthcare provider will do blood tests to check your cholesterol levels during your treatment with Jakafi.

The most common side effects of Jakafi include: low platelet count, low red blood cell counts, bruising, dizziness, headache.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Tell your healthcare provider about any side effect that bothers you or that does not go away.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had tuberculosis (TB) or have been in close contact with someone who has TB, have or had hepatitis B, have or had liver or kidney problems, are on dialysis, had skin cancer, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider. Do not drink grapefruit juice while on Jakafi.

Women should not take Jakafi while pregnant or planning to become pregnant, or if breast-feeding.

Please see Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.